ArticleJournal of ovarian research2026

Cost-effectiveness analysis of nab-paclitaxel with or without relacorilant for platinum-resistant ovarian cancer.

Shubin Lai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.